Search Results - "Chevret, Sylvie"

Bayesian adaptive clinical trials: a dream for statisticians only? by Chevret, Sylvie

“…Adaptive or ‘flexible’ designs have emerged, mostly within frequentist frameworks, as an effective way to speed up the therapeutic evaluation process. Because…”
Get full text

Summary measure of discrimination in survival models based on cumulative/dynamic time-dependent ROC curves by Lambert, Jérôme, Chevret, Sylvie

“…Assessments of the discriminative performance of prognostic models have led to the development of several measures that extend the concept of discrimination as…”
Get full text

Evaluation of the propensity score methods for estimating marginal odds ratios in case of small sample size by Pirracchio, Romain, Resche-Rigon, Matthieu, Chevret, Sylvie

“…Propensity score (PS) methods are increasingly used, even when sample sizes are small or treatments are seldom used. However, the relative performance of the…”
Get full text

Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: a systematic literature review and meta-analysis by Rubenstein, Emma, Maldini, Carla, Gonzalez-Chiappe, Solange, Chevret, Sylvie, Mahr, Alfred

“…Abstract Objectives Temporal artery biopsy (TAB) is a reference test for the diagnosis of GCA but reveals inflammatory changes only in a subset of patients…”
Get full text

Enrichment Bayesian design for randomized clinical trials using categorical biomarkers and a binary outcome by Vinnat, Valentin, Chevret, Sylvie

“…Adaptive clinical trials have been increasingly commonly employed to select a potential target population for one trial without conducting trials separately…”
Get full text

Clinical phenotypes of critically ill COVID-19 patients by Azoulay, Elie, Zafrani, Lara, Mirouse, Adrien, Lengliné, Etienne, Darmon, Michael, Chevret, Sylvie

Get full text

Comparison of models for stroke-free survival prediction in patients with CADASIL by Chhoa, Henri, Chabriat, Hugues, Chevret, Sylvie, Biard, Lucie

“…Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, which is caused by mutations of the NOTCH3 gene, has a large…”
Get full text

Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation by Bergeron, Anne, Chevret, Sylvie, Peffault de Latour, Régis, Chagnon, Karine, de Margerie-Mellon, Constance, Rivière, Frédéric, Robin, Marie, Mani, Jean, Lorillon, Gwenael, Socié, Gérard, Tazi, Abdellatif

“…Epidemiological data on late-onset noninfectious pulmonary complications (LONIPCs) following allogeneic haematopoietic stem cell transplantation (HSCT) are…”
Get full text

Eprenetapopt Plus Azacitidine in TP53 -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) by Cluzeau, Thomas, Sebert, Marie, Rahmé, Ramy, Cuzzubbo, Stefania, Lehmann-Che, Jacqueline, Madelaine, Isabelle, Peterlin, Pierre, Bève, Blandine, Attalah, Habiba, Chermat, Fatiha, Miekoutima, Elsa, Rauzy, Odile Beyne, Recher, Christian, Stamatoullas, Aspasia, Willems, Lise, Raffoux, Emmanuel, Berthon, Céline, Quesnel, Bruno, Loschi, Michael, Carpentier, Antoine F, Sallman, David A, Komrokji, Rami, Walter-Petrich, Anouk, Chevret, Sylvie, Ades, Lionel, Fenaux, Pierre

“…-mutated ( ) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very poor outcome irrespective of the treatment received, including 40%…”
Get full text

How to perform prespecified subgroup analyses when using propensity score methods in the case of imbalanced subgroups by Chatelet, Florian, Verillaud, Benjamin, Chevret, Sylvie

“…Abstract Background Looking for treatment-by-subset interaction on a right-censored outcome based on observational data using propensity-score (PS) modeling is…”
Get full text

Statistical methods for evaluating the fine needle aspiration cytology procedure in breast cancer diagnosis by El Chamieh, Carolla, Vielh, Philippe, Chevret, Sylvie

“…Statistical issues present while evaluating a diagnostic procedure for breast cancer are non rare but often ignored, leading to biased results. We aimed to…”
Get full text

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials by Hills, Robert K, DPhil, Castaigne, Sylvie, Prof, Appelbaum, Frederick R, Prof, Delaunay, Jacques, MD, Petersdorf, Stephen, MD, Othus, Megan, PhD, Estey, Elihu H, Prof, Dombret, Hervé, Prof, Chevret, Sylvie, PhD, Ifrah, Norbert, Prof, Cahn, Jean-Yves, Prof, Récher, Christian, Prof, Chilton, Lucy, PhD, Moorman, Anthony V, Prof, Burnett, Alan K, Prof

“…Summary Background Gemtuzumab ozogamicin was the first example of antibody-directed chemotherapy in cancer, and was developed for acute myeloid leukaemia…”
Get full text

G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma by Galli, Eugenio, Allain, Vincent, Di Blasi, Roberta, Bernard, Sophie, Vercellino, Laetitia, Morin, Florence, Moatti, Hannah, Caillat-Zucman, Sophie, Chevret, Sylvie, Thieblemont, Catherine

Get full text

Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites by Michonneau, David, Latis, Eleonora, Curis, Emmanuel, Dubouchet, Laetitia, Ramamoorthy, Sivapriya, Ingram, Brian, de Latour, Régis Peffault, Robin, Marie, de Fontbrune, Flore Sicre, Chevret, Sylvie, Rogge, Lars, Socié, Gérard

“…Despite improvement in clinical management, allogeneic hematopoietic stem cell transplantation (HSCT) is still hampered by high morbidity and mortality rates,…”
Get full text

Outcomes of Critically Ill Patients With Hematologic Malignancies: Prospective Multicenter Data From France and Belgium—A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study by Azoulay, Elie, Mokart, Djamel, Pène, Frédéric, Lambert, Jérôme, Kouatchet, Achille, Mayaux, Julien, Vincent, François, Nyunga, Martine, Bruneel, Fabrice, Laisne, Louise-Marie, Rabbat, Antoine, Lebert, Christine, Perez, Pierre, Chaize, Marine, Renault, Anne, Meert, Anne-Pascale, Benoit, Dominique, Hamidfar, Rebecca, Jourdain, Mercé, Darmon, Michael, Schlemmer, Benoit, Chevret, Sylvie, Lemiale, Virginie

“…PURPOSE Patients with hematologic malignancies are increasingly admitted to the intensive care unit (ICU) when life-threatening events occur. We sought to…”
Get full text

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia by Maury, Sébastien, Chevret, Sylvie, Thomas, Xavier, Heim, Dominik, Leguay, Thibaut, Huguet, Françoise, Chevallier, Patrice, Hunault, Mathilde, Boissel, Nicolas, Escoffre-Barbe, Martine, Hess, Urs, Vey, Norbert, Pignon, Jean-Michel, Braun, Thorsten, Marolleau, Jean-Pierre, Cahn, Jean-Yves, Chalandon, Yves, Lhéritier, Véronique, Beldjord, Kheira, Béné, Marie C, Ifrah, Norbert, Dombret, Hervé

“…The addition of rituximab to every phase of treatment (induction, consolidation, and maintenance) in adults with acute lymphoblastic leukemia improves…”
Get full text

Mortality prediction in intensive care units with the Super ICU Learner Algorithm (SICULA): a population-based study by Pirracchio, Romain, Dr, Petersen, Maya L, MD, Carone, Marco, PhD, Rigon, Matthieu Resche, MD, Chevret, Sylvie, Prof, van der Laan, Mark J, Prof

“…Summary Background Improved mortality prediction for patients in intensive care units is a big challenge. Many severity scores have been proposed, but findings…”
Get full text

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980 by KILADJIAN, Jean-Jacques, CHEVRET, Sylvie, DOSQUET, Christine, CHOMIENNE, Christine, RAIN, Jean-Didier

“…The overall impact of hydroxyurea (HU) or pipobroman treatments on the long-term outcome of patients with polycythemia vera (PV) has not been assessed in…”
Get full text

Challenges of using external data in clinical trials- an illustration in patients with COVID-19 by Chevret, Sylvie, Timsit, Jean-François, Biard, Lucie

“…To improve the efficiency of clinical trials, leveraging external data on control and/or treatment effects, which is almost always available, appears to be a…”
Get full text

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study by Castaigne, Sylvie, Prof, Pautas, Cécile, MD, Terré, Christine, MD, Raffoux, Emmanuel, MD, Bordessoule, Dominique, Prof, Bastie, Jean-Noel, Prof, Legrand, Ollivier, Prof, Thomas, Xavier, MD, Turlure, Pascal, MD, Reman, Oumedaly, MD, de Revel, Thierry, Prof, Gastaud, Lauris, MD, de Gunzburg, Noémie, MD, Contentin, Nathalie, MD, Henry, Estelle, Marolleau, Jean-Pierre, Prof, Aljijakli, Ahmad, MD, Rousselot, Philippe, Prof, Fenaux, Pierre, Prof, Preudhomme, Claude, Prof, Chevret, Sylvie, Prof, Dombret, Hervé, Prof

“…Summary Background The results of the addition of gemtuzumab ozogamicin, an anti-CD33 antibody conjugate, to the standard treatment for patients with acute…”
Get full text